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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.05.030Objective: Indications for surgical intervention for very limited small cell lung
cancer have not yet been determined. The objective of this study is to determine
whether resection followed by cisplatin and etoposide is feasible.
Methods: From September 1991 through December 1996, 62 patients with completely
resected small cell lung cancer who were less than 76 years of age from 17 centers were
entered in the trial. Of 62 patients, 61 were eligible, with a median follow-up of 65
months. Chemotherapy consisted of 4 cycles of cisplatin (100 mg/m2, day 1) and
etoposide (100 mg/m2, days 1-3). There were 49 (80%) male patients, 44 with clinical
stage I disease, 10 with stage II disease, and 6 with stage IIIa disease.
Results: Forty-two (69%) patients received 4 cycles of cisplatin and etoposide. No
treatment-associated mortality was noted. Median survival time was not reached in
patients with pathologic stage I disease, was 449 days in patients with stage II
disease, and was 712 days in patients with stage IIIa disease. Three-year survival
was 61% overall, 68% in patients with clinical stage I disease, 56% in patients with
stage II disease, and 13% in patients with stage IIIa disease (P  .02). Recurrence
was noted in 26 (43%) patients overall. Local failure was noted in 6 (10%) patients.
Locoregional recurrence tends to be found more frequently in patients with stage
IIIA disease. Distant failure was found in 21 (34%) patients overall. Brain metas-
tasis was found in 15% of the patients.
Conclusion: Major lung resection followed by postoperative cisplatin and etoposide is
feasible, with a favorable survival profile. Because nodal metastasis appears to be a
major prognostic factor, preoperative evaluation of nodal status remains a major con-
cern.
The prognosis of lung cancer remains poor, and this disease is the leadingcause of cancer mortality worldwide. Small cell lung cancer (SCLC) com-prises approximately 20% of lung cancer cases. Without treatment, SCLC
has the most aggressive clinical course of any other type of lung cancer, resulting
in a very short median survival time of approximately 2 to 4 months. Although
surgical resection is generally indicated for early stage non–small cell lung cancer,
this is not always the case with SCLC. This can be explained by the fact that
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would be found in most patients with SCLC at the time of
initial presentation.1 Therefore, localized forms of treat-
ment, such as surgical resection or radiation therapy, rarely
produce long-term survival, and systemic treatment with
current chemotherapy regimens is usually incorporated into
the treatment program.
Indications for surgical resection for SCLC have not yet
been determined, although several authors have reported
that a small minority of patients with limited-stage disease
and adequate lung function might benefit from surgical
resection.1-9 According to these reports, the prognosis of
resected SCLC was not so poor, especially when no patho-
logic nodal involvement was observed. The 5-year survival
ranged from 26% to 61% in these trials if the tumor was
stage I. Because SCLC tends to be disseminated and the
results of surgical intervention alone for this disease have
been reported to be poor,1,10 postoperative chemotherapy
has been used in most studies. However, the chemotherapy
was not standardized, and various chemotherapy protocols
were often used. Furthermore, most previous studies were
retrospective and thus suffered from the inherent weakness
of any retrospective assessment of a given treatment.
Because the combination of cisplatin and etoposide has
been considered to be standard in the treatment of SCLC,11
this combination was selected as a postoperative adjuvant
regimen. We conducted a prospective study of surgical
resection plus adjuvant chemotherapy for stage I through
IIIA SCLC to investigate the efficacy of this treatment
strategy.
Patients and Methods
Eligibility
Patients who were given postoperative diagnoses of SCLC histo-
logically or cytologically were eligible for enrollment in the study.
The patients had to have completely resected pathologic stage I, II,
or IIIA disease according to the TNM classification of the Inter-
national Union Against Cancer.12 Histologic typing was deter-
mined according to the World Health Organization classification.13
Inclusion criteria included an Eastern Cooperative Oncology
Group performance score of 0 or 1, age between 20 and 75 years,
no prior treatment for lung cancer, no other concurrent or previous
malignancies, a leukocyte count of greater than 3500/L, a platelet
count of greater than 100,000/L, a hemoglobin level of greater
than 9.5 g/dL, a serum creatinine level of less than 1.5 mg/dL, and
aspartate aminotransferase–alanine aminotransferase values of less
than twice the institutional upper limit of normal. Exclusion cri-
teria included a history of myocardial infarction within the past 3
months, hepatic cirrhosis, and/or severe cardiopulmonary dysfunc-
tion that required oxygen therapy. The following preoperative
investigations were performed before entry into the study: com-
puted tomographic (CT) scanning of the chest, upper abdomen,
and brain; bronchoscopy; chest plain film; radionuclide bone scan-
ning; complete blood cell count and serum chemistry; and physical
examination. Preoperative mediastinoscopy was performed in
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entering the study.
Treatment Schedule
Major lung resection, such as pulmonary lobectomy or pneumo-
nectomy, was required as a surgical procedure for SCLC. Com-
plete hilar and mediastinal lymph node dissections were recom-
mended on the basis of the lymph node map defined by Naruke and
colleagues.14 After confirming complete resection and histologic
typing of SCLC histologically, eligible patients were registered in
the study.
Chemotherapy consisted of cisplatin (100 mg/m2 on day 1) and
etoposide (100 mg/m2 on days 1-3; PE regimen). This regimen was
repeated every 4 weeks and was administered in 4 courses. The
dose was modified according to the blood cell count and renal
function on the day of chemotherapy. Chemotherapy was admin-
istered unless the leukocyte count was less than 3000/L or the
platelet count was less than 75,000/L. Chemotherapy was with-
held until the counts recovered. If grade 4 hematologic toxicity,
according to World Health Organization (WHO) criteria,15 was
seen, the dose of etoposide was reduced to 75%. Chemotherapy
was permanently discontinued at any time when the serum creat-
inine level was 2.0 mg/dL or greater or the blood urea nitrogen
level was 30 mg/dL or greater. To assess toxicity, we subjected all
patients to complete blood cell counts and blood chemistry eval-
uations, such as for aspartate aminotransferase–alanine amino-
transferase, blood urea nitrogen, and serum creatinine, as well as
chest plain film and urinalyses at least once per week during
treatment. Toxicity criteria were evaluated on the basis of the
WHO criteria.15
Patients were followed up at the outpatient department every 3
months postoperatively and underwent CT scans of the chest,
upper abdomen, and brain, as well as radionuclide bone scanning
every 6 months, even when they were asymptomatic. No postop-
erative radiotherapy was applied until relapse was apparent.
Sites of relapse were determined by clinical, radiologic, or
histologic criteria at initial recurrence. Local failure was defined as
recurrence at the primary lung site or hilar-mediastinal lymph
nodes. Distant failure was defined as recurrence in the contralateral
lung, bone, brain, liver, or other extrathoracic regions.
Statistical Analysis
The trial was designed as a prospective phase II trial. The primary
goal of the study was to estimate the survival. A sample size of 30
was considered to provide a power of 90% for detecting a signif-
icant improvement in the 3-year survival (from 20% to 50%) in a
1-sided test with an  value of .025 and a  value of .10. The
median follow-up period for 35 surviving patients was 65 months.
The length of survival was defined as the interval in months
between the day of surgical resection of lung cancer and the date
of death from any cause or the last follow-up. The survival curves
were constructed by using the Kaplan-Meier method,16 and curves
were compared with the log-rank test.
Results
Patient Characteristics
Between September 1991 and December 1996, 62 patients
were entered in this phase II trial at the 16 institutions that
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final histologic category was changed from SCLC to large cell
carcinoma. Thus, 61 patients were eligible for assessment of
survival data, and their characteristics are shown in Table 1.
The median age was 64 years (range, 22-74 years). According
to histologic typing defined by the WHO, oat cell, intermedi-
ate, and combined types were found in 9, 45, and 7 patients,
respectively. Forty-four patients had clinical stage I disease, 9
had stage II disease, and 8 had stage IIIA disease. Pathologi-
cally, stage I, II, and IIIA disease was found in 35, 8, and 18
patients, respectively.
Treatment Administration
As a surgical procedure, pulmonary lobectomy was per-
formed in 57 (93%) patients, and pneumonectomy was
performed in the other 4 patients. Among 4 pneumonecto-
mies, 3 were on the left side, and 1 was on the right side.
Complete hilar and mediastinal lymph node dissection was
TABLE 1. Patient characteristics
Total 61
Sex
Male 49
Female 12
Age (y)
Range 22-74
Median 64
Histologic subtype defined by WHO*
Oat cell type 9
Intermediate type 45
Combined type 7
Clinical stage
I 44
II 9
IIIA 8
Side of primary tumor
Right 32
Left 29
Operative procedure
Lobectomy 57
Pneumonectomy 4
Extent of lymph node dissection†
Complete hilar and mediastinum 59
Only hilar 2
Pathologic stage
I 35
II 8
IIIA 18
Performance status
0 32
1 29
*Histologic subtyping was determined on the basis of the World Health
Organization (WHO) classification. †The extent of lymph node dissection
was defined by Naruke and associates.14 performed in 59 (97%) patients.
The Journal of ThoraciA total of 204 courses were administered (Table 2).
Forty-two (69%) patients underwent a full course of che-
motherapy. The other 19 patients did not complete postop-
erative chemotherapy because of progressive disease in 3
patients, adverse effects in 7 patients, refusal of chemother-
apy in 8 patients, and death from pneumonia in 1 patient.
Treatment-Related Toxicity
No treatment-associated deaths were found. Postoperative
bronchopulmonary fistula was found in 1 (2%) patient who
underwent pulmonary lobectomy after completion of the
first cycle of chemotherapy. Chemotherapy-related toxicity
is shown in Table 3. Grade 4 toxicity was found in 9 (15%)
patients: leukopenia in 4 patients, thrombocytopenia in 2
patients, nausea in 2 patients, and cardiac failure in 1
patient. One patient died of pneumonia 2 months after the
first course of chemotherapy, but this was not considered to
be chemotherapy related.
Survival
Survival data are shown in Table 4. Among the 61 eligible
patients, 35 were still alive after a median follow-up of 65
TABLE 2. Treatment delivery
Total no. of patients 61
No. of chemotherapy courses
0 1 (2%)
1 5 (8%)
2 8 (13%)
3 5 (8%)
4 42 (69%)
TABLE 3. Chemotherapy-related toxicity in 60 eligible pa-
tients treated for resected stage I to IIIA SCLC
Toxicity
WHO grade
1 2 3 4 4 (%)
Anemia 9 29 16 0 0
Leukocytopenia 7 17 26 4 6.5
Thrombocytopenia 11 8 14 2 3.2
Infection 2 1 0 0 0
Nausea 24 13 13 2 3.3
Diarrhea 8 2 2 0 0
Azotemia 35 0 0 0 0
Renal failure 18 0 0 0 0
Stomatitis 14 1 1 0 0
Dyspnea 5 0 0 0 0
Fever 10 7 0 0 0
Skin 4 2 0 0 0
Alopecia 13 23 11 0 0
Cardiac dysfunction 5 2 1 1 1.7
CNS 1 1 1 0 0
Peripheral neuropathy 5 1 0 0 0WHO, World Health Organization; CNS, central nervous system.
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61% and 57%, respectively (Figure 1). The 5-year survival was
66%, 56%, and 13% in patients with clinical stage I, II, and
IIIA disease, respectively (Figure 2). Among the 44 patients
with clinical stage I disease, 27 were classified as having
clinical stage IA disease, and the other 17 were classified as
having clinical stage IB disease. There was no significant
difference in prognosis between clinical stage IA and IB dis-
ease. Similar results were obtained regarding the pathologic
stage. Pathologic stage I disease showed a significantly better
prognosis (Figure 3). The 5-year survivals in the 23 patients
with pathologic stage IA disease and the 12 patients with stage
TABLE 4. Survival in patients with resected SCLC who
underwent postoperative chemotherapy
Median survival time (d)
Survival
3 y 5 y
Clinical stage
IA Not reached 70% 66%
IB Not reached 65% 65%
II Not reached 56% 56%
IIIA 530 13% 13%
Pathologic stage
IA Not reached 78% 73%
IB Not reached 67% 67%
II 449 38% 38%
IIIA 712 39% 39%Figure 1. Survival curve for overall
980 The Journal of Thoracic and Cardiovascular Surgery ● MayIB disease were 73% and 67%, respectively. No significant
differences in survival were observed between patients with
pathologic stage IA and IB disease.
Patterns of failure. Recurrence was noted in 26 (43%)
patients, and the sites of initial relapse at a median fol-
low-up time of 65 months are shown according to the
pathologic stage in Table 5. Recurrence was found in 30%
of patients with stage IA disease, 25% of patients with stage
IB disease, 50% of patients with stage II disease, and 67%
of patients with stage IIIA disease.
Local failure was noted in 6 (10%) patients: 4 in the
mediastinal lymph nodes and 2 in the bronchial stump.
Locoregional recurrence tended to be found more frequently
in patients with stage IIIA disease (22%) than in patients
with stage I or II disease. Relapse at the bronchial stump
was only seen in patients with stage IIIA disease.
Distant failure was found in 22 (36%) patients overall: 6
(26%) with stage IA disease, 2 (17%) with stage IB disease, 4
(50%) with stage II disease, and 9 (50%) with stage IIIA
disease. Distant failure was most frequently noted in the brain,
followed by the liver. The incidence of brain metastasis was
15% overall, 17% in patients with stage IA disease, and 11%
in patients with stage IIIA disease. Bone metastasis was noted
exclusively in patients with stage IIIA disease.
Discrepancy between clinical and pathologic stages. Table 6
shows the relationship between the clinical stage and the
pathologic stage. Among 44 patients with clinical stage I
disease, only 33 (75%) had pathologic stage I disease, andpatients with resected SCLC.
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disease had mediastinal lymph node metastasis. According
to the Bowker test of symmetry, these differences were
statistically significant.
Discussion
This phase II trial showed that postoperative PE for patients
who underwent surgical resection of stage I to IIIA SCLC
was feasible, and the outcome was acceptable. Survival was
excellent in patients with stage I disease and did not appear
Figure 2. Survival curves for patientFigure 3. Survival curves for patients with
The Journal of Thoracito be inferior to that with chemoradiotherapy in patients
with stage II or IIIa disease.
On the basis of the results of the British Medical Re-
search Council, radical radiotherapy has been preferable to
surgical intervention for SCLC,17,18 and the indications for
surgical resection for SCLC are still controversial. An op-
eration would be indicated for limited SCLC because the
most common relapse site after radiotherapy was locore-
gional, and surgical intervention might improve local con-
trol.19 Several authors have reported that a small minority of
h resected SCLC by clinical stages.s witresected SCLC by pathologic stage.
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and postoperative chemotherapy.1-9 According to those re-
ports, the 5-year survivals were 28% to 36% overall and
26% to 61% in patients with stage I disease. However, most
of those reports were retrospective and used various com-
binations of chemotherapy. Therefore, a prospective trial of
adjuvant chemotherapy for patients with resected SCLC
using standardized chemotherapy has been needed. Our
survival data suggest that postoperative PE after major lung
resection and hilar and mediastinal lymph node dissection is
a feasible and promising treatment, especially for patients
with stage I SCLC. The 3- and 5-year survivals for patients
with stage I disease were 78% and 73%, respectively, and
the median survival time was not reached. As for patients
with stage II or IIIA disease, the results were not definitive,
and a further prospective study is needed. This study dealt
with postoperatively proved SCLC. As to the indication for
surgical intervention for preoperatively diagnosed SCLC,
controversies still remain. Our recommendation is as fol-
lows. When a patient has SCLC of clinical N1 or N2 status,
chemoradiotherapy should be considered because a survival
after an operation alone would not be good enough. Surgical
intervention should be considered, however, for patients
with clinical stage I disease because an operation followed
by chemotherapy offers a good prognosis, as shown in this
TABLE 5. Site of the first relapse by pathologic stages*
Variables Overall Stage IA
No. of patients 61 23
No. of recurrence 26 (43%) 7 (30%)
Recurrence
Local
Overall 6 (10%) 1 (4%)
Mediastinum 4 1
Bronchial stump 2 0
Distant
Overall 22 (36%) 6 (26%)
Brain 9 (15%) 4 (17%)
Bone 3 0
Liver 7 1
Lung 2 0
Small intestine 2 1
TABLE 6. Relationship between clinical and pathologic
stages
Clinical stage
Pathologic stage
P value*I II IIIA
I 33 5 6 .011
II 1 3 5
IIIA 1 0 7*P value in Bowker’s test of symmetry.
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non-SCLC postoperatively. A phase III trial comparing
chemoradiotherapy with surgical intervention followed by
chemotherapy is interesting. However, the number of pa-
tients with SCLC with clinical stage I or II disease is very
small, and we do not think it is possible to perform the phase
III trial in this population.
Because clinical stage and pathologic stage were signif-
icant prognostic factors in our trial, preoperative staging,
intraoperative staging, or both should be a major concern for
the treatment of very limited SCLC. Actually, the following
preoperative investigations were performed before entry
into the study in this cohort: CT scans of the chest, upper
abdomen, and brain; bronchoscopy; chest plain film; radio-
nuclide bone scans; complete blood cell count and serum
chemistry; and physical examination. If the diagnosis of
SCLC was made preoperatively, we recommend the same
preoperative workup as done by us in this study. Further-
more, if swollen lymph nodes are detected on thoracic CT
scans, we absolutely recommend mediastinoscopy for such
cases. As for positron emission tomography, we have no
recommendation thus far because this modality has recently
begun to be evaluated, although it could be useful for
staging N1 disease. Intraoperatively, hilar and mediastinal
lymph node sampling or dissection was performed in 59
(97%) patients. This intraoperative staging is also important
for deciding on the treatment strategy.
The site of the first relapse was another fruit of our study.
This clinical trial did not use postoperative mediastinal
irradiation or prophylactic cranial irradiation (PCI). We
should discuss the importance of these strategies for very
limited SCLC. As to locoregional recurrence, approxi-
mately 10% of the patients showed relapse in the medias-
tinal lymph nodes, bronchial stump, or both. Five percent of
Stage IB Stage II Stage IIIA
12 8 18
3 (25%) 4 (50%) 12 (67%)
1 (8%) 0 (0%) 4 (22%)
1 0 2
0 0 2
2 (17%) 4 (50%) 9 (50%)
0 (0%) 3 (38%) 2 (11%)
0 0 3
1 1 4
1 0 1
0 0 1patients with stage I or II disease eventually have locore-
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with stage IIIA disease. These results suggest that patients
with stage IIIA disease, at least, could benefit from postop-
erative mediastinal irradiation, whereas those with stage I or
II disease might not need to undergo radiotherapy. Thus,
postoperative chemoradiotherapy might be used in a future
trial for stage IIIA disease.
Auperin and associates20 reported that PCI improved
both overall survival and disease-free survival among pa-
tients with SCLC in complete remission. Surgically resected
SCLC would be considered SCLC in complete remission,
and PCI would be indicated. Overall, 15% of the patients in
our study showed brain metastasis. Even among patients
with stage IA disease, more than 10% of the patients had
brain metastasis. Therefore, PCI might be necessary for all
patients with completely resected SCLC, whereas some
authors have insisted that patients with pathologic stage IA
SCLC can be cured without any adjuvant treatment.19
Noda and coworkers21 reported that combination chemo-
therapy consisting of irinotecan (CPT-11) and cisplatin was
superior to PE for extensive SCLC. Although concurrent
radiotherapy with CPT-11 would be harmful, we would use
the new regimen for very limited SCLC, especially for stage
II or IIIA SCLC.
Major lung resection with complete hilar and mediastinal
lymph node dissection followed by postoperative PE is a
feasible treatment and results in a favorable survival profile.
Survival was especially good for patients with stage I dis-
ease. Our strategy could be used as a standard treatment arm
in a future trial for very limited SCLC.
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